UNH price forecast: DOJ scrutiny and cost pressure led to share decline

Traders Union
All News
Financial News
Unitedhealth group slides 3.73% today

Highlights

UnitedHealth Group (UNH) is trading at $328.71, well below major moving averages, indicating sustained seller pressure across all timeframes and a bearish technical setup.
The Department of Justice investigation into Medicare billing, combined with high medical cost trends and regulatory risks, heightens financial uncertainty for UNH despite reporting $113 billion in Q3 2025 revenue with 12% year-over-year growth.
Short-term outlook expects UNH to consolidate below $350–$352, with less than 20% probability of a price increase and potential downside to $320 if $327 support fails.

Portfolio shifts and regulatory scrutiny as Medicare probe intensifies

UnitedHealth Group is under an ongoing Department of Justice investigation regarding its Medicare billing practices, raising concerns about potential financial penalties. Several institutional investors notably adjusted their holdings during the second quarter, with South Dakota Investment Council, Torray Investment Partners LLC, Obermeyer Wealth Partners, and Harel Insurance Investments & Financial Services Ltd. all substantially increasing their positions, while Triglav Investments D.O.O. significantly reduced its stake. The Baron Health Care Fund repurchased UNH shares in the third quarter and reported the company generated over $113 billion in revenue in the third quarter of 2025, reflecting 12% year-over-year growth from expanding domestic memberships. UNH also continues to face high medical cost trends, rate pressures, persistent threats of Pharmacy Benefit Manager reform, and additional government investigations.

Oversold signals and elevated volatility as intraday losses mount

Momentum indicators show mixed readings: while the daily MACD points to a strong buy, the RSI at 40.28, CCI at –258.24, and BBP at –9.85 all indicate strong oversold conditions and clear seller dominance. ADX at 27.23 suggests increasing momentum on the daily chart. Today, UNH opened with a small gap down from $341.44 to $339.37, and the price has declined 3.73%, currently trading near session lows in a high-volatility environment with pronounced downward pressure after the open. This negative intraday dynamic confirms the oversold momentum signals, though MACD’s bullish daily divergence highlights uncertainty and warns of possible mean reversion.

Further downside favored as upside probability remains limited

For the coming five days, the expected trading range is $350.08 to $352.58. The probability of a price increase is very low (less than 20%), making further declines more likely. The baseline view is for the stock to consolidate sideways below the $350 – $352 area. The bullish scenario requires a close above $359, opening a move toward $370. The bearish case unfolds if $327 support is lost, with downside risk toward psychological levels near $320.

Viktoras Karapetjanc, expert at Traders Union, sees UnitedHealth Group maintaining robust fundamentals despite recent regulatory scrutiny and market headwinds. He believes that, while downward momentum and selling pressure persist, the company's strong institutional support and double-digit revenue growth reflect confidence in the underlying business model. Karapetjanc notes that the probability of an immediate reversal remains low, but should $359 be reclaimed, the outlook could quickly shift. "Although short-term risks are elevated, the stock’s long-term prospects remain attractive — I see the current consolidation as a constructive setup for patient investors if regulatory risks stabilize."

Previously it was noted that mixed momentum and range-bound action were observed, highlighting indecision among buyers and sellers. Last time we reported that the probability of an immediate breakout remained low according to momentum indicators.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.